Gut–immune–brain axis modulation of autism spectrum disorder using precision-selected probiotics
Peer-Reviewed Publication
Updates every hour. Last Updated: 9-Oct-2025 06:11 ET (9-Oct-2025 10:11 GMT/UTC)
POSTECH & ImmunoBiome identify gut–immune–brain axis as key driver beyond genetics.
SRPX2 is a chondroitin sulfate proteoglycan (CSPG) exhibiting significant N-glycosylation, which influences its conformation, interactions, and functions, as evidenced by the enhanced glycosylation and functional impact of the N327S mutation. It plays versatile roles in multiple diseases. SRPX2 promotes cancer progression (e.g., gastric, pancreatic, thyroid, glioblastoma) by enhancing proliferation, migration, invasion, and chemoresistance via pathways like TGF-β, PI3K/AKT, Wnt/β-catenin, and FAK/SRC/ERK, correlating with poor prognosis. SRPX2 also plays critical roles in neurodevelopment; mutations are linked to language disorders, autism spectrum disorder (ASD), and potentially Rolandic epilepsy (though evidence is complex and may involve interactions like GRIN2A). SRPX2, a protein characterized by sushi repeat domains, plays a crucial role in synaptogenesis and modulates complement-mediated synaptic pruning processes. Additionally, SRPX2 contributes to idiopathic pulmonary fibrosis via TGF-β signaling, angiogenesis via μPAR/integrin signaling, myocardial infarction protection by inhibiting PI3K/AKT/mTOR, and other conditions. Its context-dependent roles, e.g., pro-fibrotic in lungs vs. protective in heart, and involvement in key signaling pathways highlight its potential as a therapeutic target, though challenges like inhibitor specificity remain.
A discrete choice experiment with 1,166 Australian adults revealed preferences for medicinal cannabis (MC) access, administration, and funding. Participants favored oral formulations, lower THC levels, earlier access with strong clinical evidence, and government subsidies. Preferences often diverged from current policy, suggesting the need for broader access and support for MC as a complementary therapy.
In the era of global climate change, personal thermoregulation has become critical to addressing the growing demands for thermoadaptability, comfort, health, and work efficiency in dynamic environments. Here, we introduce an innovative three-dimensional (3D) self-folding knitted fabric that achieves dual thermal regulation modes through architectural reconfiguration. In the warming mode, the fabric maintains its natural 3D structure, trapping still air with extremely low thermal conductivity to provide high thermal resistance (0.06 m2 K W−1), effectively minimizing heat loss. In the cooling mode, the fabric transitions to a 2D flat state via stretching, with titanium dioxide (TiO2) and polydimethylsiloxane (PDMS) coatings that enhance solar reflectivity (89.5%) and infrared emissivity (93.5%), achieving a cooling effect of 4.3 °C under sunlight. The fabric demonstrates exceptional durability and washability, enduring over 1000 folding cycles, and is manufactured using scalable and cost-effective knitting techniques. Beyond thermoregulation, it exhibits excellent breathability, sweat management, and flexibility, ensuring wear comfort and tactile feel under diverse conditions. This study presents an innovative solution for next-generation adaptive textiles, addressing the limitations of static thermal fabrics and advancing personal thermal management with wide applications for wearable technology, extreme environments, and sustainable fashion.
Biological tissues like skin, arteries, and cartilage have a non-linear strain-stiffening relationship. Some biomimetic hydrogel scaffolds have been successful in effectively replicating this behavior. However, achieving structural complexity in such strain-stiffening hydrogels has been difficult. A recent Research study has demonstrated an innovative and efficient technique, immersion phase separation 3D printing, to fabricate structurally complex tissues with strain-stiffening properties. These hydrogel scaffolds can pave the way for biomimetic, patient-specific implants in the future.
It’s often mistaken for a heart attack, but Takotsubo cardiomyopathy – previously known as Broken Heart syndrome – is a serious and sometimes fatal heart condition increasingly reported in intensive care units (ICUs). Yet without a clear clinical pathway in ICUs, it’s often missed, putting critically ill patients at risk. New research from the University of South Australia shows that using electrocardiogram (ECG) patterns and blood markers could provide an early warning system for Takotsubo Syndrome in ICU patients.